Clinica Radiotherapy Center Cluj este autorizata pentru desfasurarea studiilor clinice cu beneficiu terapeutic in cadrul specialitatilor de Oncologie Medicala si Radioterapie conform autorizatiei 580/2017.

Nr. crt Nume studiu Cod protocol Localizare
1

A randomized , double-blind, placebo-controlled multi-site PHASE III trial to evaluate the efficacy and safety of Pembrolizumab in combination with cisplatin and 5-fluorouracil(5-FU)
in subjects with locally advanced unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction(EGJ).

MK-3475 590

Esofag
2

A Global Randomized Phase 3, open – label study of REGN2810 (anti-PD-1 antibody)versus platinum-based chemotherapy in first line treatment of patients with advanced or metastatic PD-L1 + Non- Small Cell Lung Cancer

R2810-ONC-1624

Plaman
3

Phase III, Open-label, multicenter, randomized study to investigate the efficacy and safety of atezolizumab compared with chemotherapy in patiens with treatment-naive advanced or recurrent (stage IIIB not amenable for multimodality treatment) or metastatic(stage IV) non-small cell lung cancer who are deemed unsuitable for platinum-containing therapy

MO29872

Plaman
4

Peace 1 Un studiu prospective, randomizat, de faza III a tratamentului de privare de androgeni, cu sau fara radioterapie locala, cu sau fara acetat de abiraterona si prednisone la pacientii ce prezinta un cancer de prostate metastazic naiv la hormononi.

PEACE 1 GETUG AFU-21

Prostata
5

Studiu clinic experimental de faza III, randomizat, dublu-orb, multicentric, asupra tratamentului adjuvant cu nivolumab sau placebo la subiectii cu cancer esofagian sau cancer de jonctiune eso-gastrica rezecat

CA 209-577

Eso-gastric

6

A phase 3 Randomized, double-blind, multicentre study of Adjuvant Nivolumab versus Placebo in Subjects with hight Invasive Urothelial Carcinoma

CA 209-274

Urotelial

 

Nr. crt Nume studiu Cod protocol Localizare
1

A phase III open-label, multicentre trial of avelumab versus platinum doublet as a first line treatment of recurrent or stage IV PD-L1+ non small cell lung cancer

EMR 100070-005

Plaman
2

A phase 3 randomized, placebo-controlled double-blind study of JNJ-56021927 in combination with a GNRH Agonist versus GNRH Agonist plus placebo in subjects with high-risk localized or locally advanced prostate cancer and treated with primary radiation therapy

PCR3003

Prostata
3

Phase 2 Randomized Double-Blind study of Veliparib in combination with Carboplatin and Etoposide as a therapy of treatment-naive extensive stage disease Small Cell Lung Cancer.

M14-361

Plaman
4 An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinibin First-Line Treatment of Patients with stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations Solar Astellas 8273-CL-0302 Pulmonar
5 Studiu de faza 3 a unui nou 5-HT3 antagonist – Palonosetron pentru pacienti cu chimioterapie cu risc crescut emetogen administrare in doua modalitati diferite: bolus 30 sec sau perfuzie IV 30 min PALO 15-17 Calitatea vietii – ANTIEMETIC
6 Studiu de faza 3, randomizat, dublu-orb, controlat cu placebo, care compara BBI608 plus Paclitaxel saptamanal cu placebo plus Paclitaxel saptamanal la pacienti adulti cu adenocarcinoma gastric si de jonctiune esogastrica (JEG) in stadiu avansat, tratat anterior BBI608-336 Gastric
7 Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine carboplatin combinations in patients ineligible to cisplatin with advanced or methastatic urothelial carcinoma. Urotelial
8 A phase III open-label, multicentre trial of avelumab in previously treated subjects as a third line treatment of recurrent, metastatic gastric adenocarcinoma EMR 100070-008 Gastric
9 Studiu de faza 3, randomizat, dublu-orb, cu PF-06439535 si paclitaxel – Carboplatin comparativ cu Bevacizumab si Paclitaxel-Carboplatin la pacienti cu NSCLC linia I B7391003 Pulmonar
10 An Open-label, randomized Phase 3 TRIAL OF Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-naïve stage IV or recurrent Non-Small Cell Lung Cancer CA 209-227 Pulmonar
11 A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor (AI) treatment CBYL719C2301 Solar 1 Mamar
12 Protocol Title a phase III, randomised double-blind, multicentre study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB8 and Avastin in subjects with metastatic or recurrent NSCLC Samsung SB 8 Plaman
13 A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin FKB238-002 Plaman
14 Nanobiotics – Studiu de faza 2/3, multicentric, randomizat pentru a compara eficacitatea NBTXR3, implantat sub forma de injectie intratumorala si activat prin radioterapie, fata de radioterapia administrate ca monoterapie la pacienti cu sarcom de tesut moale local avansat la nivelul extremitatilor si al peretelui trunchiului NBTXR3 Sarcom
15 A phase III open-label, multicentre trial of maintenance therapy with avelumab versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction EMR 100070-007 Eso-gastric
16

A Multinational, Phase III, Rnadomized, Double-blind, placebo-controlled efficacy and safety study of enzalutamide plus androgen deprivation therapy versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer

9785-CL-0335

Prostata
17

An open label, single arm, multicentre, safety study of Atezolizumab in locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract

Saul MO 29983

Urotelial
18

A phase III, randomized, multicentre, open-label, comparative study to determine the efficacy of Durvalumab or Durvalumab and Tremelimumab in combination with Platinum-Based Chemotherapy for the First-Line treatment in patients with extensive disease ( Stage IV ) Small-Cell Lung Cancer (SCLC)

Caspian Plaman

 

Conf. Dr. Kacso Gabriel, medic primar radioterapie, medic primar oncologie medicala – gabriel.kacso@amethyst-radiotherapy.com
Dr. Iacob Catalin, medic primar radioterapie, medic specialist oncologie medicala – catalin.iacob@amethyst-radiotherapy.com
Dr. Bodale Carmen, medic specialist oncologie medicala – carmen.bodale@amethyst-radiotherapy.com
Dr. Manolescu Vlad, medic specialist oncologie medicala – vlad.manolescu@amethyst-radiotherapy.com
Dr. Ungureanu Andrei, medic specialist oncologie medicala – andrei.ungureanu@amethyst-radiotherapy.com

Clinica Amethyst Cluj

Persoana contact: Monica Pop
Telefon: 0726.326.872
Adresa de email: studii.clinice@amethyst-radiotherapy.com